1.8(top 50%)
impact factor
1.4K(top 20%)
papers
54.6K(top 5%)
citations
96(top 5%)
h-index
1.9(top 50%)
impact factor
1.5K
all documents
57.1K
doc citations
151(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Doxorubicin pathwaysPharmacogenetics and Genomics20111,167
2Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamilyPharmacogenetics and Genomics2005708
3Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenetics and Genomics2006583
4A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugsPharmacogenetics and Genomics2008528
5SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics2006425
6Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stabilityPharmacogenetics and Genomics2005419
7Very important pharmacogene summaryPharmacogenetics and Genomics2011366
8Metformin pathwaysPharmacogenetics and Genomics2012366
9Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patientsPharmacogenetics and Genomics2005355
10Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cellsPharmacogenetics and Genomics2005339
11Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai populationPharmacogenetics and Genomics2009335
12CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structurePharmacogenetics and Genomics2007332
13Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-AmericansPharmacogenetics and Genomics2006326
14Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injuryPharmacogenetics and Genomics2007301
15Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissuesPharmacogenetics and Genomics2007300
16Valproic acid pathwayPharmacogenetics and Genomics2013270
17Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28Pharmacogenetics and Genomics2007259
18PharmGKB summaryPharmacogenetics and Genomics2015243
19OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidinePharmacogenetics and Genomics2008241
20Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosisPharmacogenetics and Genomics2005237
21Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenzPharmacogenetics and Genomics2005232
22The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1cPharmacogenetics and Genomics2011216
23The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stabilityPharmacogenetics and Genomics2005209
24Cytochrome P450 2C9-CYP2C9Pharmacogenetics and Genomics2010205
25Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patientsPharmacogenetics and Genomics2007204
26Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metforminPharmacogenetics and Genomics2009202
27Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in KoreansPharmacogenetics and Genomics2011188
28Clopidogrel pathwayPharmacogenetics and Genomics2010184
29PharmGKB summaryPharmacogenetics and Genomics2013184
30Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metforminPharmacogenetics and Genomics2010175
31Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participantsPharmacogenetics and Genomics2007172
32Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient settingPharmacogenetics and Genomics2013170
33Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor responsePharmacogenetics and Genomics2009168
34HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patientsPharmacogenetics and Genomics2009167
35Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stabilityPharmacogenetics and Genomics2005166
36Generation of gene knockouts and mutant models in the laboratory rat by ENU-driven target-selected mutagenesisPharmacogenetics and Genomics2006161
37??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapyPharmacogenetics and Genomics2005160
38Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scalesPharmacogenetics and Genomics2009160
39HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsPharmacogenetics and Genomics2010160
40Significance of a common single nucleotide polymorphism in exon 10 of the follicle-stimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulationPharmacogenetics and Genomics2005159
41Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient populationPharmacogenetics and Genomics2005155
42The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humansPharmacogenetics and Genomics2011153
43PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivityPharmacogenetics and Genomics2006151
44Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenzPharmacogenetics and Genomics2006145
45Genome-wide association studies in pharmacogenomicsPharmacogenetics and Genomics2013144
46Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseasesPharmacogenetics and Genomics2005143
47Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency dataPharmacogenetics and Genomics1999142
48PharmGKB summaryPharmacogenetics and Genomics2012141
49The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjectsPharmacogenetics and Genomics2005139
50Celecoxib pathwaysPharmacogenetics and Genomics2012138